Skip to main content
Passa alla visualizzazione normale.


Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver disease

  • Authors: Salvatore Petta; Giada Sebastiani; Mauro Viganò; Javier Ampuero; Vincent Wai-Sun Wong; Jerome Boursier; Annalisa Berzigotti; Elisabetta Bugianesi; Anna Ludovica Fracanzani; Calogero Cammà; Marco Enea; Marraud des Grottes; Vito Di Marco; Ramy Younes; Aline Keyrouz; Sergio Mazzola; Yuly Mendoza; Grazia Pennisi; Manuel Romero-Gomez; Antonio Craxì; Victor de Ledinghen
  • Publication year: 2021
  • Type: Articolo in rivista
  • OA Link:


Background & Aims Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events. Methods We performed a retrospective analysis of consecutive patients with NAFLD (n=1039) with a histologic diagnosis of F3–F4 fibrosis and/or LSMs>10 KPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19–63 months). Results Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02–1.04; P<.001), HCC (HR, 1.03; 95% CI, 1.00–1.04; P=.003), and liver-related death (HR, 1.02; 95% CI, 1.02–1.03; P=.005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05–2.51; P=.04), HCC (HR, 1.72; 95% CI, 1.01–3.02; P=.04), overall mortality (HR, 1.73; 95% CI, 1.11–2.69; P=.01), and liver-related mortality (HR, 1.96; 95% CI, 1.10–3.38; P=.02). Conclusions In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality.